Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Kopsaftis

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Urology and Nephrology|January 14, 2017
Prostate cancer outcomes and delays in careMichael E O'Callaghan, Zumin Shi, Tina Kopsaftis, et al.
BJU International|November 17, 2011
Comparative analysis of three risk assessment tools in Australian patients with prostate cancerDavid J Tamblyn, Samarth Chopra, Changhong Yu, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2021
PSA response to antiandrogen withdrawal: a systematic review and meta-analysisAlwin Soo, Michael E O'Callaghan, Tina Kopsaftis, et al.
Australian Family Physician|February 2, 2008
Abnormal PSA tests--delays in referralAlan M F Stapleton, Richard L Johns, Tina Kopsaftis, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 30, 2013
Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer deathZumin Shi, Carole B Pinnock, Stephen Kinsey-Trotman, et al.
World Journal of Urology|May 12, 2018
Prostate cancer mortality is high in the elderly and can be reduced by selective individualized curative treatmentKim Moretti, Sina Vatandoust, Ganessan Kichenadasse, et al.
BJU International|April 1, 2018
Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registrySina Vatandoust, Ganessan Kichenadasse, Michael O'Callaghan, et al.
Oncotarget|November 19, 2015
Erratum: Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcomeDamien A Leach, Eleanor F Need, Roxanne Toivanen, et al.
Oncotarget|May 13, 2015
Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcomeDamien A Leach, Eleanor F Need, Roxanne Toivanen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Urology and Nephrology|January 14, 2017
Prostate cancer outcomes and delays in careMichael E O'Callaghan, Zumin Shi, Tina Kopsaftis, et al.
BJU International|November 17, 2011
Comparative analysis of three risk assessment tools in Australian patients with prostate cancerDavid J Tamblyn, Samarth Chopra, Changhong Yu, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2021
PSA response to antiandrogen withdrawal: a systematic review and meta-analysisAlwin Soo, Michael E O'Callaghan, Tina Kopsaftis, et al.
Australian Family Physician|February 2, 2008
Abnormal PSA tests--delays in referralAlan M F Stapleton, Richard L Johns, Tina Kopsaftis, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 30, 2013
Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer deathZumin Shi, Carole B Pinnock, Stephen Kinsey-Trotman, et al.
World Journal of Urology|May 12, 2018
Prostate cancer mortality is high in the elderly and can be reduced by selective individualized curative treatmentKim Moretti, Sina Vatandoust, Ganessan Kichenadasse, et al.
BJU International|April 1, 2018
Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registrySina Vatandoust, Ganessan Kichenadasse, Michael O'Callaghan, et al.
Oncotarget|November 19, 2015
Erratum: Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcomeDamien A Leach, Eleanor F Need, Roxanne Toivanen, et al.
Oncotarget|May 13, 2015
Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcomeDamien A Leach, Eleanor F Need, Roxanne Toivanen, et al.
Pageof 1